Welfarism versus extra-welfarism: can the choice of economic evaluation approach impact on the adoption decisions recommended by economic evaluation studies?

James Buchanan, Sarah Wordsworth
Author Information
  1. James Buchanan: Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Headington, Oxford, OX3 7LF, UK, james.buchanan@dph.ox.ac.uk.

Abstract

A long-running debate surrounds the equivalence of the welfarist and extra-welfarist approaches to economic evaluation. There is a growing belief that the extra-welfarist approach may not necessarily provide all the information that decisionmakers require in certain contexts, e.g. evaluation of complex interventions. As the number of these interventions being evaluated increases, it is crucial that the most appropriate economic evaluation approach is used to enable decisionmakers to be confident in their adoption decisions. We conducted a literature review to evaluate the potential for the choice of economic evaluation approach to impact on the adoption decisions recommended by economic evaluation studies. We found that for every five studies applying both approaches, one shows limited or no concordance in economic evaluation results: the different approaches suggest conflicting adoption decisions, and there is no pattern to which approach provides the most convincing adoption evidence. Only one study in ten indicates which results will best inform adoption decisions. We conclude that the choice of approach can significantly impact on the adoption decisions recommended by economic evaluation studies, with conflicting results creating confusion over whether or not interventions provide good value for money. Health economists rarely provide sufficient guidance to decisionmakers to alleviate this confusion.

References

  1. Med Decis Making. 2006 Sep-Oct;26(5):434-46 [PMID: 16997923]
  2. Br Med J (Clin Res Ed). 1985 Aug 3;291(6491):326-9 [PMID: 3160430]
  3. Pharmacoeconomics. 1997 Nov;12(5):565-77 [PMID: 10174323]
  4. Health Econ. 2013 Mar;22(3):258-71 [PMID: 22308053]
  5. Am J Prev Med. 2012 Oct;43(4):385-91 [PMID: 22992356]
  6. Genet Med. 2008 Sep;10(9):648-54 [PMID: 18978674]
  7. Value Health. 2002 Jul-Aug;5(4):338-46 [PMID: 12102696]
  8. Neuromodulation. 2005 Jul;8(3):155-61 [PMID: 22151484]
  9. Health Educ Res. 2005 Dec;20(6):676-87 [PMID: 15781446]
  10. Eur J Public Health. 2012 Dec;22(6):869-73 [PMID: 23132876]
  11. Pharmacoeconomics. 2005;23(5):423-32 [PMID: 15896094]
  12. Pharmacoeconomics. 2013 May;31(5):361-7 [PMID: 23529207]
  13. Pharmacoeconomics. 1999 Nov;16(5 Pt 1):499-520 [PMID: 10662396]
  14. Health Policy. 1991 Feb;17(1):1-23 [PMID: 10113574]
  15. Spine (Phila Pa 1976). 1994 Sep 15;19(18 Suppl):2101S-2106S [PMID: 7801189]
  16. Soc Sci Med. 1995 Aug;41(4):483-9 [PMID: 7481942]
  17. Health Econ. 2002 Jan;11(1):55-70 [PMID: 11788982]
  18. J Hypertens. 1992 Sep;10(9):1063-70 [PMID: 1328366]
  19. J Clin Epidemiol. 1997 Jul;50(7):813-22 [PMID: 9253393]
  20. Health Econ Policy Law. 2010 Jan;5(Pt 1):113-21 [PMID: 20050223]
  21. Dev Health Econ Public Policy. 1996;4:1-245 [PMID: 10158916]
  22. J Health Econ. 2000 Jul;19(4):439-59 [PMID: 11010234]
  23. Pharmacogenomics. 2003 May;4(3):231-9 [PMID: 12718713]
  24. Arch Dermatol. 1998 Dec;134(12):1602-8 [PMID: 9875201]
  25. Work. 2012;41 Suppl 1:2315-20 [PMID: 22317061]
  26. Int J Technol Assess Health Care. 1991;7(1):12-21 [PMID: 1903360]
  27. J Environ Public Health. 2009;2009:107927 [PMID: 20049165]
  28. Pharmacoeconomics. 1998 Apr;13(4):389-96 [PMID: 10178663]
  29. Eur J Health Econ. 2004 Oct;5(3):199-202 [PMID: 15452734]
  30. Bipolar Disord. 2014 Sep;16(6):557-82 [PMID: 24917477]
  31. J Health Econ. 1999 Dec;18(6):681-708 [PMID: 10847930]
  32. J Health Econ. 2002 Sep;21(5):827-43 [PMID: 12349884]
  33. Soc Sci Med. 1998 Jan;46(1):1-12 [PMID: 9464663]
  34. BMJ. 1998 Mar 28;316(7136):1013-4 [PMID: 9550969]
  35. Health Econ Policy Law. 2010 Jan;5(Pt 1):91-111 [PMID: 19706221]
  36. Pharmacoeconomics. 1996 Aug;10(2):114-22 [PMID: 10163414]

Grants

  1. DRF-2011-04-021/Department of Health
  2. 085475/Wellcome Trust
  3. 076113/Wellcome Trust
  4. 090532/Z/09/Z/Wellcome Trust

MeSH Term

Choice Behavior
Cost-Benefit Analysis
Decision Making
Delivery of Health Care
Economics, Medical
Humans

Word Cloud

Created with Highcharts 10.0.0evaluationeconomicadoptionapproachdecisionsapproachesprovidedecisionmakersinterventionschoiceimpactrecommendedstudiesextra-welfaristoneconflictingresultscanconfusionlong-runningdebatesurroundsequivalencewelfaristgrowingbeliefmaynecessarilyinformationrequirecertaincontextsegcomplexnumberevaluatedincreasescrucialappropriateusedenableconfidentconductedliteraturereviewevaluatepotentialfoundeveryfiveapplyingshowslimitedconcordanceresults:differentsuggestpatternprovidesconvincingevidencestudytenindicateswillbestinformconcludesignificantlycreatingwhethergoodvaluemoneyHealtheconomistsrarelysufficientguidancealleviateWelfarismversusextra-welfarism:studies?

Similar Articles

Cited By